AGIOS PHARMACEUTICALS, INC.AGIOEarnings & Financial Report

Nasdaq · pharmaceutical industry

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

Revenue

$20.0M

Gross Profit

$18.1M

Operating Profit

$-121.6M

Net Profit

$-108.0M

Gross Margin

90.6%

Operating Margin

-608.9%

Net Margin

-541.1%

YoY Growth

86.1%

EPS

$-1.86

Financial Flow

AGIOS PHARMACEUTICALS, INC. Q4 2025 Financial Summary

AGIOS PHARMACEUTICALS, INC. reported revenue of $20.0M for Q4 2025, with a net profit of $-108.0M (-541.1% margin). Cost of goods sold was $1.9M, operating expenses totaled $139.7M.

Key Financial Metrics

Total Revenue	$20.0M
Net Profit	$-108.0M
Gross Margin	90.6%
Operating Margin	-608.9%
Report Period	Q4 2025

AGIOS PHARMACEUTICALS, INC. Annual Revenue by Year

AGIOS PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $54.0M).

Year	Annual Revenue
2025	$54.0M
2024	$36.5M
2023	$26.8M
2022	$14.2M

Income Statement

	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Revenue	$8.2M	$8.6M	$9.0M	$10.7M	$8.7M	$12.5M	$12.9M	$20.0M
YoY Growth	46.0%	28.4%	21.2%	51.1%	6.6%	44.6%	43.7%	86.1%

Balance Sheet

	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Assets	$849.7M	$773.1M	$1.79B	$1.66B	$1.56B	$1.47B	$1.39B	$1.30B
Liabilities	$105.8M	$112.6M	$165.1M	$122.2M	$89.0M	$101.7M	$101.4M	$104.1M
Equity	$743.9M	$660.5M	$1.63B	$1.54B	$1.47B	$1.37B	$1.28B	$1.19B